病院退院時に抗精神病薬とベンゾジアゼピンを併用処方する
Maxime Demourgues1, Alexandre Richaud2, Julie Thiec2
1Hôpital Charles-Perrens, Bordeaux, France; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000 Bordeaux, France.
L'Encephale
|February 18, 2026
まとめ
従来の鎮静性抗精神病薬 (CS-AP) とベンゾジアゼピン (BZD) の併用は,精神科退院時に,特に短期間の入院 (≤14日) 後に一般的です. この高い罹患率は,患者の安全性や,野外診療での薬剤副作用の可能性について懸念を喚起しています.
科学分野:
- 精神科医は精神病を患っている.
- 臨床薬局 臨床薬局について
- 医薬品監視 医薬品監視
背景:
- 抗精神病薬とベンゾジアゼピン (BZD) は,精神病薬性により併用すると,鎮静,めまい,認知障害のリスクを伴う.
- 精神病院退院時に抗精神病薬とBZDの併用処方量を最小限に抑えるべきであり,特にシアメマジン,レボメプロマジン,ロキサピンなどの従来の鎮静性抗精神病薬 (CS-AP) による併用は特に重要です.
研究 の 目的:
- 精神病院退院時のCS-AP,長期抗精神病薬 (LT-AP),およびBZDの処方箋の有病率を決定する.
- CS-APとBZDの併用処方に関連する要因を特定する.
主な方法:
- 2022-2023年の精神科入院からの退院処方箋を分析した遡及的研究.
- 退院時に抗精神病薬とBZDの使用を登録することによって評価された流行.
- CS-APとBZDの共同処方に関連する要因を特定するために使用される多変数ロジスティック回帰.
主要な成果:
- 5,733件の解禁処方箋のうち,CS-APは38.7%,LT-APは69.1%,BZDは48.3%であった.
- CS-APとBZDの併用は14.8%の症例で,CS-AP,LT-AP,BZDの併用は10.1%の症例で発生した.
- CS-APとBZDの併用処方薬は,短期間の入院 (≤14日) と精神科緊急治療室の初期入院と有意に関連していました.
結論:
- 精神科退院時に,特に短期滞在後に,BZDの共同処方によるCS-APの高い流行は,病院からコミュニティケアへの移行を改善することを必要としています.
- BZDと併用するシアメマジン (最も一般的なCS-AP) の頻繁な処方箋は,潜在的な副作用のために注意を払う必要があります.
- 短期間の入院や緊急入院は,退院時の薬剤管理が最適でないことに寄与する可能性があります.
キーワード:
抗精神病薬は,抗精神病薬として使われています.抗精神病薬は,抗精神病薬として使われます.抗不安薬 (アンキソリチックス) とはアクソリチクスの不安医薬使用者団体ベンゾジアゼピンはベンゾジアゼピンです.ベンゾジアゼピンは,ベンゾジアゼピンの薬物の組み合わせは,薬物の組み合わせです.ファルマコエピデミオロギー学ファルマコエピデミオロジー学 (Pharmacoépidémiologie) とは,薬剤学 (Pharmacoépidémiologie) とは,薬剤学 (Pharmacoépidémiologie) とは,薬剤学 (Pharmacoépidémiologie) とは,薬剤学 (Pharmacoépidémiologie) とは,関連する概念動画
CNS Depressants: Barbiturates and Benzodiazepines
1.5K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.5K
Sedatives and Hypnotics Drugs: Benzodiazepines
991
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
991
Drug Therapy
316
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
316
Anxiolytic Drugs: Benzodiazepines and Buspirone
2.6K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.6K
Psychosis: Goals of Pharmacotherapy
555
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
555
Discharge Summary Forms
1.3K
The discharge summary is crucial as it enables a smooth transition from a healthcare facility to a patient's home or another care setting. This critical document facilitates seamless continuity of care, ensuring patients receive the necessary support and attention.
Here's a detailed look at the key components and guidelines for preparing a discharge summary:
Here's a detailed look at the key components and guidelines for preparing a discharge summary:
1.3K


